Research Centre

Go back to current news

December 07 , 2018

The Canadian Hemophilia Society – Bayer ADVANCE Canada Research Program was created to engage Canadian hemophilia treaters in activities to identify and research key issues in the ageing hemophilia population.

This program is offered in partnership with ADVANCE Canada (ADVANCE: age-related developments and co-morbidities in hemophilia) who’s Mission is as follows:

To improve the health and Quality of Life (QoL) of older Canadians living with hemophilia by underpinning our actions and recommendations in the rigour of science conducted with and for older Canadians living with hemophilia.

In order to optimize management of age-related co-morbidities in the adult hemophilia population, ADVANCE Canada will foster patient-centred research, and disseminate scientific information to assist Canadian hemophilia-treating physicians.

Life expectancy for people with hemophilia has improved and is now approaching that of the general population. The growing population of older people with hemophilia will therefore increasingly face age-related morbidities such as cardiovascular diseases, malignancies, liver disease, and bone and joint related disease, as well as the lifestyle and psychosocial factors that accompany and predispose to many of these conditions. Little is known about how to manage cardiovascular disease, cancer, dementia, and other age-related diseases in the older hemophilia population. Recognizing the importance of how age-related diseases might affect people with hemophilia, this research program’s goal is to support research that will help inform how management and treatment should best be adapted for people ageing with hemophilia.

The research program will support studies that aim to:

  • Identify and provide insight into key issues associated with the ageing hemophilia population
  • Identify how management of age-related co-morbidities should be adapted to those with hemophilia
  • Create and deliver evidence-based information to health care practitioners (HCPs), the public and policy makers that will lead to improved care and QoL for older Canadians living with hemophilia

The Research Grants are made possible thanks to generous financial support from Bayer Canada. Bayer creates innovative products, breakthrough treatments and healthier alternatives to improve quality of life for Canadians through products that fight disease, protect crops and animals, and provide high-performance materials for numerous daily life uses. The CHS is proud to be in a partnership with Bayer Canada in order to offer this important Research Program.

The primary intent of this program is to offer one or two $30,000 research grants, to a maximum of $60,000 for one year.

Depending upon the number and quality of applications, funding for different amounts is possible, as is the offering of more than one research grant, within however, the allotted total budget stated above.  

Eligibility To be eligible the applicant must be a physician or Ph.D. with professional experience in a hemophilia treatment centre (HTC) or other comparable settings in which care has been provided to people with hemophilia and other inherited bleeding disorders. Professionals who have appointments in universities and who can dedicate time to research are encouraged to apply. Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization.

The proposed research must have relevance to current practice in bleeding disorders care and may incorporate a broad spectrum of quantitative and qualitative research methods addressing professional practice with individuals, families, groups and communities, organizational issues, public health, and education.

The research studies should aim to provide better data and tools to help the treaters assist patients in successful ageing.

Interest areas and methodologies might include but are not limited to:

  • musculoskeletal problems – loss of joint and muscle function and chronic pain that can impair daily activities and worsen quality of life.
  • cardiovascular disease – risk factors most frequently seen in hemophilia patients include hypertension, or high blood pressure, and being overweight.
  • viral infections such as HIV and hepatitis – these conditions imply treatment with antiviral drugs, which may affect patients’ kidneys and liver.
  • chronic kidney disease – this condition causes hypertension. Because of hemophilia patients’ deficient blood clotting ability, it could increase their risk of a brain hemorrhage.
  • chronic pain – this condition also implies treatments that could adversely affect hemophilia patients.
  • cancer – chemotherapy can cause loss of white blood cells, which could worsen hemophilia patients’ tendency to bleed.

Multidisciplinary Collaboration Collaboration with multidisciplinary care providers and/or between two or more hemophilia centres is accepted and encouraged. Collaboration efforts are welcome as co-applicants and may include, for example, nursing, social work, physical therapy and genetics. It thus may be possible for a hemophilia centre team to jointly submit a cooperative research project. Additionally, inter-regional applications will be considered.

Applications and Deadline: February 8, 2019. All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before February 8, 2019. If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the successful applicants will be announced by March, 2019.

Multidisciplinary and multi-centre applications are welcomed.  Please note that if a multidisciplinary or multi-centre project is sought, you are encouraged to indicate in the application how the project would proceed if a grant was to be awarded to only one portion of the proposed project.

Grants will be offered for a one-year period to begin in April 2019.

Click here for more information.


Search Research
News Archives

Name or keyword: 7